ClinicalTrials.gg
CompletedNCT04941807Updated Apr 23, 2024Results posted

Use of Platelet-rich Plasma (PRP) Therapy in Patients With Brittle Nail Syndrome

A Phase 4 interventional study of Platelet-rich plasma and Platelet-poor plasma in Nail Diseases, sponsored by Weill Medical College of Cornell University. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-23.

Sponsored by Weill Medical College of Cornell University · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Mar 2021, registered Jun 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
11
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to assess the efficacy and safety of platelet-rich plasma therapy for brittle nail syndrome

02

Conditions studied

  • Nail Diseases

Keywords

  • Nails
  • brittle nail syndrome
  • platelet-rich plasma
03

In context

Lead sponsor

Weill Medical College of Cornell University is the lead sponsor of 892 studies on the registry; 165 are open to participants now.

Of its 123 completed or terminated interventional studies of FDA-regulated products, 94 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who have been diagnosed with brittle nails
  • Must understand and voluntarily sign an form
  • Must be male or female and aged 18-95 years at time of consent
  • Must be able to adhere to the study visit schedule and other protocol requirements
  • A nail clipping with histopathology that is negative for the presence of dermatophyte infection
  • Patient must present with at least a score of 2 on the PGA scale.

Exclusion criteria

Exclusion Criteria:

  • Inability of the patient to provide written for any reason.

    • Subject has psoriasis, lichen planus, dermatophyte infection or other confounding abnormalities that are severe enough to result in a clinically abnormal fingernail
    • Use of any medication within 90 days prior to start of study
    • Inability to abstain for nail polishes, nail gels during the study period
    • Subject is pregnant or planning pregnancy.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    Platelet-rich plasma

    The proximal nail fold is cleansed with alcohol and platelet-rich plasma obtained from the patient is injected using a 1ml syringe and 30g needle, 0.1-0.2 ml of platelet-rich plasma is injected into 8 proximal nail folds.

    Device: Platelet-rich plasma

  • Placebo comparator
    Platelet-poor plasma

    The proximal nail fold is cleansed with alcohol and platelet-poor plasma obtained from the patient is injected using a 1ml syringe and 30g needle, 0.1-0.2 ml of platelet-poor plasma is injected into 2 proximal nail folds.

    Device: Platelet-poor plasma

Interventions

  • DevicePlatelet-rich plasma

    Blood will be drawn from a vein in the patient's arm into an 11 ml Eclipse platelet-rich plasma Tube. The blood is processed using a centrifuge machine from eclipse medical. After centrifugation, the platelet poor portion will be separated from the platelet-rich portion. The proximal nail folds are cleansed with alcohol. Using a 1ml syringe and 30g needle, 0.1-0.2 ml of platelet-rich plasma is injected into 8 proximal nail folds.

  • DevicePlatelet-poor plasma

    Blood will be drawn from a vein in the patient's arm into an 11 ml Eclipse platelet-rich plasma Tube. The blood is processed using a centrifuge machine from eclipse medical. After centrifugation, the platelet poor portion will be separated from the platelet-rich portion. The proximal nail folds are cleansed with alcohol. Using a 1ml syringe and 30g needle, 0.1-0.2 ml of platelet-poor plasma is injected into 2 proximal nail folds.

06

What researchers measure

Primary outcomes

  1. Physician Global Improvement Assessment (PGIA)

    The PGIA will be based on a comparison of photographs taken at baseline to the nails at week 16 of follow-up. The Physician Global Improvement Score (PGIA) evaluates the improvement of lamellar splitting, transverse splitting, ridges, longitudinal grooves, longitudinal splitting, and nail thickness in target fingernails. Change is classified as excellent, good, or fair, or categorized as no improvement or worsening.

    Time frame: At 16 weeks

Secondary outcomes

  1. Change From Baseline in Qualify of Life, as Measured by the Modified Nail Psoriasis Quality of Life Scale (NPQ10) Between Baseline and Week 16

    The modified NPQ10 comprises 10 questions gauging the impact of brittle nail syndrome on daily activities. Each response is scored from 0 to 2, resulting in a total score between 0 and 20, where higher values indicate a more significant impact. The final scores are converted to percentages, ranging from 0% to 100%, with higher percentages indicating higher functional difficulty experienced. The absolute change in NPQ10 percentage score from baseline to week 16 is reported here.

    Time frame: Subjective assessments of quality of life impact due to nail health will be collected at baseline and week 16

07

Results

Posted Apr 23, 2024

Participant flow

Participants were recruited from one location in the United States

Participant flow — Overall Study
MilestonePlatelet-rich PlasmaPlatelet-poor Plasma
Started1111
Completed1010
Not completed11
Withdrew: Lost to follow-up11

Outcome measures

PrimaryPhysician Global Improvement Assessment (PGIA)

The PGIA will be based on a comparison of photographs taken at baseline to the nails at week 16 of follow-up. The Physician Global Improvement Score (PGIA) evaluates the improvement of lamellar splitting, transverse splitting, ridges, longitudinal grooves, longitudinal splitting, and nail thickness in target fingernails. Change is classified as excellent, good, or fair, or categorized as no improvement or worsening.

Time frame:
At 16 weeks
Reported as:
Count of units · Fingernails
Physician Global Improvement Assessment (PGIA)
FingernailsPlatelet-rich PlasmaPlatelet-poor Plasma
Excellent improvement52
Good improvement71
Fair improvement92
No improvement4213
Worse102
SecondaryChange From Baseline in Qualify of Life, as Measured by the Modified Nail Psoriasis Quality of Life Scale (NPQ10) Between Baseline and Week 16

The modified NPQ10 comprises 10 questions gauging the impact of brittle nail syndrome on daily activities. Each response is scored from 0 to 2, resulting in a total score between 0 and 20, where higher values indicate a more significant impact. The final scores are converted to percentages, ranging from 0% to 100%, with higher percentages indicating higher functional difficulty experienced. The absolute change in NPQ10 percentage score from baseline to week 16 is reported here.

Time frame:
Subjective assessments of quality of life impact due to nail health will be collected at baseline and week 16
Reported as:
Mean · percentage
Change From Baseline in Qualify of Life, as Measured by the Modified Nail Psoriasis Quality of Life Scale (NPQ10) Between Baseline and Week 16
percentageAll Groups
Change From Baseline in Qualify of Life, as Measured by the Modified Nail Psoriasis Quality of Life Scale (NPQ10) Between Baseline and Week 1610 (0 to 60)

Adverse events

Collected over 16 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Platelet-rich Plasma0/10 (0%)0/10 (0%)4/10 (40%)
Platelet-poor Plasma0/10 (0%)0/10 (0%)4/10 (40%)
Most frequent other events
Most frequent other events
EventPlatelet-rich PlasmaPlatelet-poor Plasma
Subungual hematomaSkin and subcutaneous tissue disorders3/102/10
OnychomadesisSkin and subcutaneous tissue disorders2/102/10
LeukonychiaSkin and subcutaneous tissue disorders1/100/10
Beau's line(s)Skin and subcutaneous tissue disorders1/100/10

Baseline characteristics

Age, Continuous
Age, Continuous(years)Platelet-rich PlasmaPlatelet-poor PlasmaTotal
Mean67.8 ± 667.8 ± 667.8 ± 6
Sex/Gender, Customized
Sex/Gender, Customized(participants)Platelet-rich PlasmaPlatelet-poor PlasmaTotal
Female101010
Male111
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Platelet-rich PlasmaPlatelet-poor PlasmaTotal
American Indian or Alaska Native000
Asian111
Native Hawaiian or Other Pacific Islander000
Black or African American000
White101010
More than one race000
Unknown Race or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Platelet-rich PlasmaPlatelet-poor PlasmaTotal
Hispanic or Latino222
Not Hispanic or Latino999
Unknown Ethnicity or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Platelet-rich PlasmaPlatelet-poor PlasmaTotal
United States111111
Physician Global Assessment (PGA)
Physician Global Assessment (PGA)(score on a scale)Platelet-rich PlasmaPlatelet-poor PlasmaTotal
Mean3.16 (0 to 12)2.7 (0 to 10)3.06 (0 to 12)
Nail Superficial Abnormality Index (NSAI)
Nail Superficial Abnormality Index (NSAI)(score on a scale)Platelet-rich PlasmaPlatelet-poor PlasmaTotal
Mean3.5 (0 to 8)3.4 (0 to 8)3.5 (0 to 8)
Modified Nail Psoriasis Quality of Life Scale (NPQ10)
Modified Nail Psoriasis Quality of Life Scale (NPQ10)(Percentage)Platelet-rich PlasmaPlatelet-poor PlasmaTotal
Mean16.5 (0 to 75)16.5 (0 to 75)16.5 (0 to 75)
08

Study locations

1 site
  • Weill Cornell Medicine
    New York, New York 10021, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Individual participant data that underlie the results reported in this article, after deidentification.

Supporting information: Study protocol

Time frame: Immediately following publication.

Access criteria: Anyone who wishes to access the data.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2021 to primary completion in Apr 2023, 25 months.

Results were first posted in Apr 2024, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2021
First posted
Jun 28, 2021
StartActual
Mar 4, 2021
Primary completionActual
Apr 12, 2023
CompletionActual
Apr 12, 2023
Results first posted
Apr 23, 2024
Last update
Apr 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04941807
Collaborators
Eclipse Aesthetics, LLC
Responsible party
Sponsor
First posted
Jun 28, 2021
Start date
Mar 4, 2021
Primary completion
Apr 12, 2023
Completion
Apr 12, 2023
Results posted
Apr 23, 2024
Last update
Apr 23, 2024

Study contacts

Shari R Lipner, MD, PhD
principal investigator · Weill Medical College of Cornell University

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion